Wedge Capital Management’s AbbVie ABBV Stock Holding History

Wedge Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$33.9M	Buy	134,579 +9,380	+7%	+$2.02M	0.56%	64
2026 Q1	$27.2M	Buy	125,199 +1,459	+1%	+$324K	0.5%	85
2025 Q4	$28.3M	Sell	123,740 -6,019	-5%	-$1.37M	0.51%	85
2025 Q3	$30M	Sell	129,759 -35,033	-21%	-$7.13M	0.51%	73
2025 Q2	$30.6M	Buy	164,792 +5,666	+4%	+$1.05M	0.55%	79
2025 Q1	$33.3M	Sell	159,126 -1,673	-1%	-$325K	0.65%	65
2024 Q4	$28.6M	Sell	160,799 -3,753	-2%	-$690K	0.51%	72
2024 Q3	$32.5M	Sell	164,552 -47,887	-23%	-$8.94M	0.56%	69
2024 Q2	$36.4M	Sell	212,439 -6,199	-3%	-$1.03M	0.65%	63
2024 Q1	$39.8M	Buy	218,638 +12,673	+6%	+$2.18M	0.64%	67
2023 Q4	$31.9M	Sell	205,965 -8,155	-4%	-$1.19M	0.57%	57
2023 Q3	$31.9M	Sell	214,120 -14,492	-6%	-$2.13M	0.63%	55
2023 Q2	$30.8M	Sell	228,612 -9,655	-4%	-$1.42M	0.49%	61
2023 Q1	$38M	Sell	238,267 -9,596	-4%	-$1.47M	0.64%	34
2022 Q4	$40.1M	Sell	247,863 -8,172	-3%	-$1.25M	0.65%	30
2022 Q3	$34.4M	Buy	256,035 +8,532	+3%	+$1.22M	0.58%	63
2022 Q2	$37.9M	Buy	247,503 +23,055	+10%	+$3.52M	0.6%	45
2022 Q1	$36.4M	Sell	224,448 -53,026	-19%	-$7.7M	0.49%	73
2021 Q4	$37.6M	Buy	277,474 +6,257	+2%	+$739K	0.46%	69
2021 Q3	$29.3M	Sell	271,217 -12,955	-5%	-$1.48M	0.38%	109
2021 Q2	$32M	Sell	284,172 -8,562	-3%	-$964K	0.39%	85
2021 Q1	$31.7M	Buy	+292,734	New	+$31.3M	0.38%	112
2020 Q3	–	Sell	-3,955	Closed	-$388K	–	532
2020 Q2	$388K	Buy	3,955 +459	+13%	+$40.4K	0.01%	382
2020 Q1	$266K	Sell	3,496 -468,323	-99%	-$39.9M	﹤0.01%	421
2019 Q4	$41.8M	Sell	471,819 -13,115	-3%	-$1.09M	0.47%	77
2019 Q3	$36.7M	Buy	484,934 +47,265	+11%	+$3.24M	0.43%	75
2019 Q2	$31.8M	Buy	+437,669	New	+$34.4M	0.36%	99
2019 Q1	–	Sell	-2,313	Closed	-$213K	–	573
2018 Q4	$213K	Sell	2,313 -96	-4%	-$8.44K	﹤0.01%	537
2018 Q3	$228K	Buy	2,409 +166	+7%	+$15.7K	﹤0.01%	553
2018 Q2	$208K	Buy	+2,243	New	+$219K	﹤0.01%	568
2017 Q3	–	Sell	-575,701	Closed	-$41.7M	–	568
2017 Q2	$41.7M	Sell	575,701 -141,671	-20%	-$9.52M	0.4%	67
2017 Q1	$46.7M	Buy	+717,372	New	+$45.1M	0.45%	71
2016 Q2	–	Sell	-702,481	Closed	-$40.1M	–	564
2016 Q1	$40.1M	Buy	+702,481	New	+$39.2M	0.42%	68
2015 Q2	–	Sell	-893,210	Closed	-$52.3M	–	594
2015 Q1	$52.3M	Buy	893,210 +156,595	+21%	+$9.46M	0.52%	55
2014 Q4	$48.2M	Buy	736,615 +21,550	+3%	+$1.36M	0.48%	72
2014 Q3	$41.3M	Sell	715,065 -156,635	-18%	-$8.7M	0.44%	72
2014 Q2	$49.2M	Sell	871,700 -48,350	-5%	-$2.54M	0.5%	51
2014 Q1	$47.3M	Buy	920,050 +18,300	+2%	+$925K	0.5%	64
2013 Q4	$47.6M	Buy	901,750 +57,675	+7%	+$2.83M	0.5%	59
2013 Q3	$37.8M	Buy	844,075 +4,420	+0.5%	+$196K	0.44%	88
2013 Q2	$34.7M	Buy	+839,655	New	+$36.7M	0.42%	91

Other funds holding ABBV

LMFP

Larry Mathis Financial Planning Phoenix, Arizona $124B AUM

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

HCM

Hamlin Capital Management New York $4.45B AUM 22.95% 1-Year Est. Return

AAMU

AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return

HPC

HM Payson & Co Portland, Maine $7.54B AUM 31.34% 1-Year Est. Return

CRM

Cardano Risk Management Rotterdam, Netherlands $13B AUM 49.44% 1-Year Est. Return

CNB

Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Wedge Capital Management's ABBV Position: Q2 2026 in Review

Wedge Capital Management increased its AbbVie (ABBV) stake by 7.5% in Q2 2026, buying an estimated $2.02M and bringing the position to 134,579 shares worth $33.9M. The position accounts for 0.56% of the portfolio, ranked #64.

Wedge Capital Management first reported a position in ABBV in Q2 2013 and has held it in 41 quarters since. The position peaked at $52.3M in Q1 2015. 937 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Wedge Capital Management held 134,579 shares of AbbVie worth $33.9M as of Q2 2026.
Wedge Capital Management bought 9,380 AbbVie shares in Q2 2026, an estimated $2.02M.
AbbVie made up 0.56% of Wedge Capital Management's portfolio in Q2 2026, its #64 holding.
Wedge Capital Management first reported a position in AbbVie in Q2 2013 and has held it in 41 quarters since.
Wedge Capital Management's AbbVie position peaked at $52.3M in Q1 2015.
937 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Wedge Capital Management's 13F filing for Q2 2026, filed 10 Jul 2026.